GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TYK Medicines Inc (HKSE:02410) » Definitions » EBIT

TYK Medicines (HKSE:02410) EBIT : HK$-231.52 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TYK Medicines EBIT?

TYK Medicines's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was HK$-117.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-231.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TYK Medicines's annualized ROC % for the quarter that ended in Jun. 2024 was -22.26%. TYK Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -199.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TYK Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -2.19%.


TYK Medicines EBIT Historical Data

The historical data trend for TYK Medicines's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TYK Medicines EBIT Chart

TYK Medicines Annual Data
Trend Dec22 Dec23
EBIT
-344.56 -409.56

TYK Medicines Quarterly Data
Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
EBIT Get a 7-Day Free Trial -92.35 -96.57 - -114.52 -117.00

Competitive Comparison of TYK Medicines's EBIT

For the Biotechnology subindustry, TYK Medicines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TYK Medicines's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TYK Medicines's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TYK Medicines's EV-to-EBIT falls into.



TYK Medicines EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-231.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TYK Medicines  (HKSE:02410) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TYK Medicines's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-401.976 * ( 1 - 0% )/( (1803.212 + 1807.912)/ 2 )
=-401.976/1805.562
=-22.26 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=655.032 - 59.486 - ( 230.834 - max(0, 1490.739 - 283.073+230.834))
=1803.212

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=569.811 - 66.007 - ( 170.425 - max(0, 1517.631 - 213.523+170.425))
=1807.912

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

TYK Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-468.016/( ( (210.182 + max(-1329.007, 0)) + (259.705 + max(-1366.528, 0)) )/ 2 )
=-468.016/( ( 210.182 + 259.705 )/ 2 )
=-468.016/234.9435
=-199.20 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 49.719) - (59.486 + 0 + 1319.24)
=-1329.007

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 39.559) - (66.007 + 0 + 1340.08)
=-1366.528

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TYK Medicines's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-231.519/10569.829
=-2.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TYK Medicines EBIT Related Terms

Thank you for viewing the detailed overview of TYK Medicines's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


TYK Medicines Business Description

Traded in Other Exchanges
N/A
Address
No. 1278 Mingzhu Road, Room 1403-2, Floor 14, Tower A, Changxing World Trade Building, Zhejiang Province, Changxing Economic Development Zone, Huzhou, CHN
TYK Medicines Inc is a drug discovery research and development centre. The company and its subsidiaries are principally engaged in the research, development and commercialization of pharmaceutical products.
Executives
Nan Jing Yi Da Tou Zi Guan Li You Xian Gong Si
Nan Jing Yi Da Zi Ben Guan Li Qi Ye You Xian He Huo
Jiang Su Yi Da Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si
Wu Yusheng 2201 Interest of corporation controlled by you
Zhu Julia Ming 2202 Interest of your spouse
Zheng Zhou Tai Ji Hong Nuo Yi Yao Gu Fen You Xian Gong Si 2101 Beneficial owner
Zhang Xing Li Yuan Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
He Chao 2201 Interest of corporation controlled by you
Bei Jing Hou Ji Jing Qiao Chuang Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Rong Chen Hou Ji Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Zhang Xing Xing Zhang Chan Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

TYK Medicines Headlines

No Headlines